Amgen (AMGN) Capital Expenditures (2009 - 2026)

Amgen has reported Capital Expenditures for 18 years, with the latest figure at $712.0 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 73.24% year-over-year to $712.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 billion (up 69.07% YoY), and the FY2025 full-year result was $1.9 billion, up 69.53% from the prior year.
• Capital Expenditures for Q1 2026 stood at $712.0 million, up from $642.0 million in the prior quarter.
• The five-year high for Capital Expenditures was $712.0 million in Q1 2026, with the low at $160.0 million in Q3 2022.
• Average Capital Expenditures over 5 years is $336.1 million, with a median of $271.0 million recorded in 2023.
• Year-over-year, Capital Expenditures tumbled 33.88% in 2022 and surged 81.05% in 2023.
• Tracing AMGN's Capital Expenditures over 5 years: stood at $340.0 million in 2022, then fell by 26.76% to $249.0 million in 2023, then surged by 49.0% to $371.0 million in 2024, then soared by 73.05% to $642.0 million in 2025, then climbed by 10.9% to $712.0 million in 2026.
• The last three Capital Expenditures figures came in at $712.0 million (Q1 2026), $642.0 million (Q4 2025), and $436.0 million (Q3 2025), per Business Quant data.

Peer Comparison